BCPCBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering Balchem Corp. hold a median 12-month price target of $215 — +24.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 22 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Balchem Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Value (45): The shares cost a lot relative to the profits and assets behind them.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BCPC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $190 → $215 |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | $5.10 → $5.16 |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2025 | Rothschild & Co | Initiates | Neutral | — |
| 22 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Aug 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BCPC appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Balchem Corp. returned +11.0% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 23% of US stocks
Cheaper than 23% of US stocks
Cheaper than 14% of US stocks
Higher than 56% of US stocks
Higher than 55% of US stocks
Higher than 45% of US stocks
Higher than 80% of US stocks
Higher than 78% of US stocks
Higher than 70% of US stocks
Higher than 88% of US stocks
Higher than 81% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Balchem Corp. has a market value of $5.4B and an enterprise value of $5.5B.
Revenue in the twelve months to 31 Mar 2026: $1.1B. The latest quarter grew 11.2% year on year.
Net income over the same four quarters: $158.1M, a 15.0% net margin.
Diluted earnings per share, trailing twelve months: $4.87.
Free cash flow in the twelve months to 31 Mar 2026: $176.0M, after $44.2M of capital spending.
Balchem Corp. spent $118.0M on share buybacks and $30.8M on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 33.6×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.25%, paying out 19% of earnings.
Balchem Corp. employs 1,379 people — $767K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Balchem Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Balchem Corporation reported financial results for its fiscal third quarter ended September 30, 2026.
Why it matters — The report provides BCPC watchers with an update on the company’s quarterly financial results.
Balchem Corporation announced a conference call for Friday, October 23, 2026, at 11:00 a.m. Eastern Time to review its third-quarter 2026 results.
Why it matters — BCPC watchers can note the scheduled date and time for the company's review of its quarterly results.
Balchem Corporation announced it will participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. The company is a global specialty ingredient manufacturer for health and nutrition markets.
Why it matters — The conference participation gives Balchem an opportunity to present to investors and industry participants, which may be of interest to those following the company.
Balchem Corporation reported Q2 results with EPS of $1.49, beating estimates by $0.07, and revenue that surpassed consensus by $15 million while rising 11% year over year. All business segments posted growth, ranging from a minimum of 8.9% to a peak of 15% in Animal Nutrition & Health.
Why it matters — A BCPC watcher would care because double-digit revenue growth and beats across every segment indicate broad-based, company-wide momentum in the latest quarter.
Seeking Alpha published the transcript of Balchem Corporation's Q2 2026 earnings call.
Why it matters — Earnings call transcripts provide direct insight into management's commentary on quarterly results and the company's outlook.
The 3 Wall Street analysts covering Balchem Corp. have a median 12-month price target of $215, with estimates ranging from $165 to $242. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Balchem Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Balchem Corp. 93 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Balchem Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +24.1% from the last close, and Ticker Nerd's factor model ranks Balchem Corp. 93 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Balchem Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCPC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $242 over the next 12 months.
Balchem Corp. returned +11.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Balchem Corporation is a specialty ingredients and solutions company that develops, manufactures, and distributes performance products for nutrition, food, pharmaceuticals, animal health, medical device sterilization, plant nutrition, and industrial applications. The company operates through three main segments: Human Nutrition and Health, which supplies ingredients and delivery systems used in food, beverage, and supplement formulations; Animal Nutrition and Health, which provides nutritional ingredients and technologies for livestock and companion animal markets; and Specialty Products, which includes packaged performance gases and chemical products used in healthcare and other industrial settings.
The most recent item we track (GlobeNewsWire, 23 Oct 2026): "Balchem Corporation Reports Third Quarter 2026 Financial Results". Balchem Corporation reported financial results for its fiscal third quarter ended September 30, 2026.
Balchem Corporation is a specialty ingredients and solutions company that develops, manufactures, and distributes performance products for nutrition, food, pharmaceuticals, animal health, medical device sterilization, plant nutrition, and industrial applications. The company operates through three main segments: Human Nutrition and Health, which supplies ingredients and delivery systems used in food, beverage, and supplement formulations; Animal Nutrition and Health, which provides nutritional ingredients and technologies for livestock and companion animal markets; and Specialty Products, which includes packaged performance gases and chemical products used in healthcare and other industrial settings. Balchem Corporation serves customers worldwide by combining formulation expertise, ingredient functionality, and application-specific technologies. Founded in 1967 and headquartered in Montvale, New Jersey, Balchem Corporation plays a broad role in specialty ingredient supply chains across health, nutrition, and industrial markets.
CEO Mr. Theodore Lee Harris · 1,379 employees · United States · https://www.balchem.com
